Ticker > Company >

MPS Pharmaa share price

MPS Pharmaa Ltd.

BSE: 531686 SECTOR: Pharmaceuticals & Drugs  12.09 K   14   0

2.04
-0.10 (-4.67%)
BSE: 01 Sep 4:00 PM

Price Summary

Today's High

₹ 2.05

Today's Low

₹ 2.04

52 Week High

₹ 4.33

52 Week Low

₹ 2.04

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3.9 Cr.

Enterprise Value

11.17 Cr.

No. of Shares

1.91 Cr.

P/E

0

P/B

4.59

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  0.44

CASH

0.01 Cr.

DEBT

7.27 Cr.

Promoter Holding

35.89 %

EPS (TTM)

₹  -0.47

Sales Growth

0%

ROE

-34.92 %

ROCE

-9.06%

Profit Growth

20.88 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 YearNA
3 YearNA
5 Year-100%

Profit Growth

1 Year20.88%
3 Year21.91%
5 Year5.92%

ROE%

1 Year-34.92%
3 Year-23.43%
5 Year-31.02%

ROCE %

1 Year-9.06%
3 Year-9.95%
5 Year-14.97%

Debt/Equity

3.6947

Price to Cash Flow

-6.16

Interest Cover Ratio

-448.065

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 35.89 16.04
Mar 2025 35.89 16.04
Dec 2024 35.89 16.04
Sep 2024 35.89 16.04
Jun 2024 35.89 16.04
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 0 days.

 Limitations

  • Company has a poor ROE of -23.4346722071447% over the past 3 years.
  • Company has a poor ROCE of -9.95012297204186% over the past 3 years
  • Company has high Debt to Equity ratio of 3.6947.
  • Company has low Interest coverage ratio of -448.065.
  • Company has negative cash flow from operations of -0.633193.
  • The company has a low EBITDA margin of -415.88033976834% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 0 0 0 0 0
Total Expenditure 0.2 0.19 0.19 0.19 0.19
Operating Profit -0.2 -0.19 -0.19 -0.19 -0.19
Other Income 0 0 0.04 0 0
Interest 0 0 0 0 0
Depreciation 0.04 0.04 0.04 0.04 0.04
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.23 -0.23 -0.18 -0.23 -0.23
Tax -0.01 -0.01 0 0.05 -0.01
Profit After Tax -0.22 -0.22 -0.18 -0.28 -0.22
Adjusted EPS (Rs) -0.12 -0.12 -0.09 -0.15 -0.12

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 0 0 0.03 0 0
Total Expenditure 0.68 4.13 0.71 0.95 0.8
Operating Profit -0.67 -4.13 -0.67 -0.95 -0.8
Other Income 0.01 0.2 0.26 0.02 0.09
Interest 0 0 0 0 0
Depreciation 0.57 0.56 0.51 0.15 0.15
Exceptional Items 0 0 0 0 0
Profit Before Tax -1.24 -4.49 -0.93 -1.07 -0.85
Tax -0.07 -0.08 -0.79 -0.02 -0.02
Net Profit -1.17 -4.42 -0.14 -1.05 -0.83
Adjusted EPS (Rs.) -0.61 -2.31 -0.07 -0.55 -0.43

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 19.11 19.11 19.11 19.11 19.11
Total Reserves -10.75 -15.16 -15.29 -16.32 -17.14
Borrowings 0 0 0 0 0
Other N/C liabilities 0.74 0.69 0.25 0.23 0.22
Current liabilities 7.3 6.66 6.08 7.17 7.74
Total Liabilities 16.41 11.3 10.16 10.19 9.94
Assets
Net Block 5.26 4.68 4.17 4.14 4.01
Capital WIP 5.02 3.9 3.42 3.4 3.26
Intangible WIP 0 0 0 0 0
Investments 0.92 0.54 0.54 0.54 0.54
Loans & Advances 0.01 0.01 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 5.2 2.19 2.03 2.1 2.12
Total Assets 16.41 11.3 10.16 10.19 9.94
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -1.24 -4.49 -0.56 -1.05 -0.84
Adjustment 0.59 0.58 0.51 0.15 0.15
Changes in Assets & Liabilities 0.15 2.98 -4.3 0.04 0.06
Tax Paid 0 0 0 0 0
Operating Cash Flow -0.49 -0.93 -4.34 -0.87 -0.63
Investing Cash Flow 0.46 1.54 0.46 -0.1 0.12
Financing Cash Flow 0.03 -0.61 3.88 0.96 0.51
Net Cash Flow 0 0 0 -0.01 0

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 35.89 35.89 35.89 35.89 35.89
omkam pharmaceuticals pri... 25.65 25.65 25.65 25.65 25.65
peeyush kumar aggarwal 10.24 10.24 10.24 10.24 10.24
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 64.11 64.11 64.11 64.11 64.11
dhiru builders and promot... 5.23 5.23 5.23 5.23 5.23
geeta garg 1.99 1.99 1.99 1.99 1.99
pataliputra international... 17.51 17.51 17.51 17.51 17.51
sampark securities pvt lt... 1.06 1.06 1.06 1.06 1.06
sangeetha s 6.23 6.23 6.23 6.23 6.23
sneha garg 2.01 2.01 2.01 2.01 2.01
n l rungta (huf) . - 1.25 - - -
n l rungta (huf) 1.16 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

MPS Pharmaa - Quaterly Results 12 Aug, 4:49 PM MPS Pharmaa - Quaterly Results 12 Aug, 4:49 PM MPS Pharmaa - Quaterly Results 12 Aug, 4:49 PM MPS Pharmaa - Quaterly Results 12 Feb, 2:11 PM MPS Pharmaa - Quaterly Results 12 Feb, 2:11 PM MPS Pharmaa - Quaterly Results 12 Feb, 2:11 PM MPS Pharmaa informs about board meeting 25 Jan, 4:18 PM MPS Pharmaa informs about statement of investor complaints 11 Oct, 4:51 PM MPS Pharmaa informs about certificate 11 Oct, 4:39 PM Advik Laboratories informs about notice of book closure 4 Sep, 5:06 PM MPS Pharmaa informs about outcome of board meeting 13 Aug, 5:28 PM MPS Pharmaa informs about outcome of board meeting 13 Aug, 2:53 PM MPS Pharmaa - Quaterly Results 13 Aug, 2:11 PM MPS Pharmaa - Quaterly Results 13 Aug, 2:11 PM Advik Laboratories informs about board meeting 14 May, 5:30 PM MPS Pharmaa - Quaterly Results 13 Feb, 5:47 PM MPS Pharmaa - Quaterly Results 13 Feb, 5:47 PM MPS informs about earnings presentation 16 May, 12:16 PM MPS Pharmaa informs about compliance certificate 18 Apr, 1:09 PM MPS Pharmaa - Quaterly Results 3 Feb, 2:54 PM MPS Pharmaa - Quaterly Results 3 Feb, 2:54 PM MPS Pharmaa - Quaterly Results 3 Feb, 2:54 PM Advik Laboratories informs about board meeting 16 Nov, 5:22 PM Advik Laboratories informs about newspaper publication 14 Nov, 5:07 PM Advik Laboratories informs about disclosure 10 Nov, 12:33 PM Advik Lab - Quaterly Results 21 May, 5:30 PM Advik Lab - Quaterly Results 21 May, 5:30 PM Advik Lab - Quaterly Results 21 May, 5:30 PM Advik Laboratories planning to raise funds via various modes 11 Apr, 12:37 PM Advik Laboratories informs about newspaper publication 4 Mar, 4:14 PM Advik Laboratories submits EGM notice 3 Mar, 4:44 PM Advik Laboratories informs about outcome of board meeting 19 Feb, 3:46 PM Advik Laboratories informs about outcome of board meeting 19 Feb, 3:43 PM Advik Lab - Quaterly Results 10 Jan, 3:07 PM Advik Lab - Quaterly Results 10 Jan, 3:07 PM Advik Lab - Quaterly Results 10 Jan, 3:07 PM Advik Lab - Quaterly Results 13 Oct, 5:24 PM Advik Lab - Quaterly Results 13 Oct, 5:24 PM Advik Lab - Quaterly Results 13 Oct, 5:24 PM Advik Laboratories informs about outcome of board meeting 31 Aug, 11:59 AM Advik Laboratories informs about AGM notice 8 Dec, 3:41 PM Advik Laboratories informs about book closure 2 Dec, 11:04 AM Advik Laboratories informs about compliance certificate 27 Oct, 10:49 AM Advik Laboratories informs about disclosure 7 Apr, 3:31 PM

MPS Pharmaa Stock Price Analysis and Quick Research Report. Is MPS Pharmaa an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse MPS Pharmaa. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). MPS Pharmaa has a PE ratio of -4.35153583617748 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. MPS Pharmaa has ROA of -8.2602% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. MPS Pharmaa has a Current ratio of 0.2741.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. MPS Pharmaa has a ROE of -34.9177%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. MPS Pharmaa has a Debt to Equity ratio of 3.6947 which means that the company has high proportion of debt in its capital.

  • Sales growth: MPS Pharmaa has reported revenue growth of 0% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of MPS Pharmaa for the current financial year is 0%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for MPS Pharmaa is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of MPS Pharmaa is Rs -0.4688. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of MPS Pharmaa in Ticker for free. Also, one can get the intrinsic value of MPS Pharmaa by using Valuation Calculators, which are available with a Finology ONE subscription. 

MPS Pharmaa FAQs

Q1. What is MPS Pharmaa share price today?
Ans: The current share price of MPS Pharmaa is Rs 2.04.

Q2. What is the market capitalisation of MPS Pharmaa?
Ans: MPS Pharmaa has a market capitalisation of Rs 3.8987256 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of MPS Pharmaa?
Ans: The PE ratio of MPS Pharmaa is -4.35153583617748 and the P/B ratio of MPS Pharmaa is 4.58839406207827, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of MPS Pharmaa share?
Ans: The 52-week high share price of MPS Pharmaa is Rs 4.33, and the 52-week low share price of MPS Pharmaa is Rs 2.04.

Q5. Does MPS Pharmaa pay dividends?
Ans: Currently, MPS Pharmaa does not pay dividends. Dividend yield of MPS Pharmaa is around 0%.

Q6. What are the face value and book value of MPS Pharmaa shares?
Ans: The face value of MPS Pharmaa shares is Rs 10, while the book value per share of MPS Pharmaa is around Rs 0.4446. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of MPS Pharmaa?
Ans: MPS Pharmaa has a total debt of Rs 7.2741245 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of MPS Pharmaa?
Ans: The ROE of MPS Pharmaa is -34.9177% and ROCE of MPS Pharmaa is -9.0583%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is MPS Pharmaa a good buy for the long term?
Ans: The MPS Pharmaa long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is MPS Pharmaa undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the MPS Pharmaa appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check MPS Pharmaa’s financials?
Ans: You can review MPS Pharmaa’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about MPS Pharmaa
X